ASX News

Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product

Melbourne (Australia) – 2nd December 2020. Telix has been granted HREC approval and received CTN clearance by the TGA to commence Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients with advanced prostate cancer.

Telix Pharmaceuticals Limited is pleased to announce it has been granted Human Research Ethics Committee (HREC) approval and received Clinical Trial Notification (CTN) clearance by the Therapeutic Goods Administration (TGA) to commence its first-in-human Phase I study of the Company’s next generation prostate cancer therapy product TLX592, in patients with advanced prostate cancer.

TLX592 has been developed using Telix’s proprietary RADmAb® engineered antibody technology. Like the Company’s existing TLX591 antibody development program, TLX592 targets prostate specific membrane antigen (PSMA) – a target that is almost ubiquitously expressed by prostate cancer cells. TLX592 has been engineered to clear far more rapidly from a patient’s circulation, making it suitable for use as a targeting agent for 225Ac (actinium-225). Actinium is a potent therapeutic alpha (α) emitting radionuclide and treatment with α-emitting radionuclides is commonly referred to “Targeted Alpha Therapy” or “TAT”.

The Phase I ‘CUPID’ study is a single centre, open-label trial that will evaluate the safety and tolerability, pharmacokinetics, biodistribution and radiation dosimetry of TLX592 in patients with advanced prostate cancer.

Telix CEO, Dr Chris Behrenbruch said: “We are delighted to have been granted approval to commence the Phase I CUPID study for TLX592. Telix’s proprietary RADmAb® technology fundamentally underpins our ability to develop new TAT treatments for patients with metastatic cancer. In the case of TLX592, the clinical objective is to treat patients with prostate cancer that have a low disease burden for which alpha therapy is ideally suited, as well as potentially treating patients that no longer respond to conventional lutetium PSMA therapy (177Lu-PSMA). Telix has one of the biggest TAT pipelines in the industry and we are pleased to see our R&D efforts heading into the clinic.”

To read the full ASX release, please click here.

For our related investor briefing, please click here.

More Articles

ASX News

First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 25th January 2021. Telix Pharmaceuticals announces the first U.S. patients have been dosed...

Corporate Spotlight

Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific

22nd January 2021 – Corporate Spotlight | Telix Pharmaceuticals welcomes Dr Danielle Meyrick as Chief Medical Officer, Asia Pacific

Corporate Spotlight

ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target

Burnaby, Canada and Indianapolis, USA, January 12, 2021 – ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer...

ASX News

Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product

Melbourne (Australia) and Indianapolis, IN (USA) – 16th December 2020. Telix has filed a New Drug Submission (NDS) with Health Canada...

ASX News

Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance

Melbourne (Australia) – 16th December 2020. Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field...

ASX News

Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging

Melbourne (Australia) – 14th December 2020. Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration...

ASX News

Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data

Melbourne (Australia) – 14th December 2020. Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an...

ASX News

Telix Granted TGA Priority Review for Prostate Cancer Imaging

Melbourne (Australia) – 7th December 2020. Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the...

ASX News

Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging

Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership...

ASX News

Telix Receives Approval for First-In-Human Study of Next Generation Prostate Cancer Therapy Product

Melbourne (Australia) – 2nd December 2020. Telix has been granted HREC approval and received CTN clearance by the TGA to...

ASX News

Investor Briefing – TheraPharm GmbH Acquisition

Melbourne (Australia) – 1st December 2020. Telix Pharmaceuticals Provides Investor Briefing: TheraPharm GmbH Acquisition

ASX News

Telix Pharmaceuticals Limited Acquires TheraPharm GmbH

Melbourne (Australia) and Baar (Switzerland) –  30th November 2020. Telix announces it has entered into an agreement with Scintec Diagnostics...

ASX News

Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 24th November 2020. Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit...